What is
Cibinqo?
What is
Cibinqo
Cibinqo (abrocitinib) is an oral janus kinase (JAK) inhibitor that reduces inflammation and itch.1
What is Janus kinase (JAK)?
JAKs are enzymes, a type of protein, that help transmit signals to influence hematopoiesis (formation of blood cellular components) and function of immune cells via the JAK/STAT signaling pathway.2,3
Normally, the JAK/STAT pathway is activated when cytokines (a type of signaling proteins) are released in the body and bind to their receptors.4,5 JAK enzymes will then be activated to trigger a series of signaling events, leading to the initiation of various important cellular processes such as hematopoiesis, immune fitness, tissue repairment, and inflammation.3–5
The role of oral Janus kinase (JAK) inhibitors
Disorders of specific immune cells could lead to an elevated production of cytokines.3,6 This could cause an overexpression of JAK enzymes in your body, leading to abnormally high JAK/STAT pathway activity.3 Cibinqo works by blocking the specific overreactive JAK/STAT activity, thus reducing symptoms of itch as an effect.2,3
Cibinqo may be the option for you if the condition of your skin (eg, itch or inflammation) does not improve.1 Consult your doctor for more information.
References
- CIBINQO® (abrocitinib) Package Leaflet: Information for the patient. Pfizer Corporation Hong Kong Limited: Version September 2022.
- CIBINQO® (abrocitinib) Prescribing Information. Pfizer Corporation Hong Kong Limited: Version September 2022.
- Hu X, et al. Signal Transduct Target Ther 2021;6:402.
- Chovatiya R & Paller AS. J Allergy Clin Immunol 2021;148:927-940.
- Clark JD, et al. J Med Chem 2014;57:5023-5038.
- Klonowska J, et al. Int J Mol Sci 2018;19:3086.